By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyax is granting GE Healthcare rights to develop and commercialize c-Met imaging peptides for potential use in patient selection under a deal announced today.

Under the terms of the deal, GE will pay biopharmaceutical firm Dyax upfront, milestone, and royalty payments. Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.